BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsCompany update

ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board

Related news

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BDSXBiodesix2025-09-11 12:00 EST

Biodesix Announces One-for-Twenty Reverse Stock Split

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

VRAXVirax Biolabs2026-07-09 11:30 EST

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

DGXQuest Diagnostics2026-04-16 13:00 EST

City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers

FLGTFulgent Genetics, Inc.2026-03-17 20:31 EST

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2025-12-22 21:10 EST

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

INBSIntelligent Bio Solutions2025-12-12 15:30 EST

Intelligent Bio Solutions Inc. Announces Reverse Stock Split

View all latest news

Bluejay Diagnostics

Bluejay Diagnostics is a medical diagnostics company focused on rapid testing and blood-based diagnostic tools. Its business is centered on bringing point-of-care information to clinical settings rather than developing therapeutics.

Recent company news

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-05-07 20:01 EST

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Stock data

Close
1.15 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States